https://nypost.com/2020/03/19/old-malaria-drug-hydroxychloro... Additionally the federal government has asked this company to produce 20 million tablets, so this has some hope. Amneal Pharmaceuticals accelerates hydroxychloroquine sulfate production in response to COVID-19 outbreak (3.57 +0.38) : Amneal Pharmaceuticals is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate. Amneal is ramping up production of hydroxychloroquine sulfate at several of its manufacturing sites and expects to produce approx. 20 mln tablets between now and mid-April. Those tablets will be made available nationwide through Amneal's existing retail and wholesale customers, as well as through direct sales to larger institutions in need. Today, Amneal's hydroxychloroquine sulfate tablets are approved by the FDA to treat malaria, rheumatoid arthritis, lupus, childhood arthritis, and other autoimmune diseases. Hydroxychloroquine is not approved for the treatment of COVID-19; however, it has been identified as a possible treatment for COVID-19, and the US government has requested its immediate availability.